Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series

ACTA MEDICA INDONESIANA · Vol. 53 No. 3 (2021)

ISSN
2338-2732, 0125-9326
Terbit
2021-10-04
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

One of the main causes of death in COVID-19 is the dysregulation of the host’s immune system which leads to cytokine storm, a potentially fatal systemic inflammatory syndrome. Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is produced in response to infections and tissue injuries and is believed to play a pivotal role in the event of a cytokine storm, as signified by its increase in the process. Considering the role of IL-6 as a pro-inflammatory cytokine in the process of cytokine storm in COVID-19, perceiving IL-6 as a therapeutic target could prove to be promising. Tocilizumab is a monoclonal antibody that competitively inhibits the binding of IL-6 to its receptor (IL-6R). The use of IL-6R blocker is recommended for severe COVID-19 patients in the latest therapeutic guideline published by the World Health Organization (WHO), but the timing of the administration has not been specified. While previous studies about the use of tocilizumab in COVID-19 patients have shown various results, these studies do not emphasize on plasma IL-6 levels when deciding the time of tocilizumab administration. In this case series, we present three patients with moderate to severe COVID-19 infections that receive tocilizumab as an adjunct to the standard of care therapy. This case series introduces the novel idea that the timely use of tocilizumab as signified by plasma IL-6 levels in moderate to severe COVID-19 patients could potentially improve overall clinical condition and increase survival rate.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 277 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • National Research and Innovation Agency
  • Institut Agama Islam Negeri Bone
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kuntjoro HarimurtiAfiliasi tidak diketahui15
Hamzah ShatriAfiliasi tidak diketahui10
Muhammad Khifzhon AzwarAfiliasi tidak diketahui7
Noto DwimartutieAfiliasi tidak diketahui7
Cleopas Martin RumendeAfiliasi tidak diketahui7
Rahmi IstantiAfiliasi tidak diketahui6
Jessica MarsigitAfiliasi tidak diketahui6
Ikhwan RinaldiAfiliasi tidak diketahui6
Mira YuliantiNational Research and Innovation Agency6
Rudi PutrantoAfiliasi tidak diketahui6
Dyah PurnamasariAfiliasi tidak diketahui6
Roza MulyanaAfiliasi tidak diketahui5
Rensa RensaAfiliasi tidak diketahui5
Eka Dian SafitriAfiliasi tidak diketahui5
Siti Rizny F SaldiAfiliasi tidak diketahui5
Em YunirUniversity of Indonesia5
Sally Aman NasutionAfiliasi tidak diketahui5
Nur RiviatiAfiliasi tidak diketahui4
Aulia RizkaAfiliasi tidak diketahui4
Esthika DewiastyAfiliasi tidak diketahui4
Ari Fahrial SyamAfiliasi tidak diketahui4
Simon SalimAfiliasi tidak diketahui4
Idrus AlwiAfiliasi tidak diketahui4
Pradana SoewondoAfiliasi tidak diketahui4
Juferdy KurniawanAfiliasi tidak diketahui4
Purwita W LaksmiAfiliasi tidak diketahui3
Tirza Z TaminAfiliasi tidak diketahui3
Rudy HidayatAfiliasi tidak diketahui3
Muhammad YaminInstitut Agama Islam Negeri Bone3
Cleopas M RumendeAfiliasi tidak diketahui3
Dadang MakmunAfiliasi tidak diketahui3
Murdani AbdullahAfiliasi tidak diketahui3
Gurmeet SinghAfiliasi tidak diketahui3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series</dc:title>
	<dc:creator>Tenda, Eric Daniel</dc:creator>
	<dc:creator>Andrian, Setiabakti</dc:creator>
	<dc:creator>Albert, Sedjahtera</dc:creator>
	<dc:creator>Asaf, Moses M</dc:creator>
	<dc:creator>Pitoyo, Ceva W</dc:creator>
	<dc:creator>Setiati, Siti</dc:creator>
	<dc:creator>Subekti, Imam</dc:creator>
	<dc:subject xml:lang="en-US">case series</dc:subject>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">interleukin-6</dc:subject>
	<dc:subject xml:lang="en-US">timely</dc:subject>
	<dc:subject xml:lang="en-US">tocilizumab</dc:subject>
	<dc:description xml:lang="en-US">One of the main causes of death in COVID-19 is the dysregulation of the host’s immune system which leads to cytokine storm, a potentially fatal systemic inflammatory syndrome. Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is produced in response to infections and tissue injuries and is believed to play a pivotal role in the event of a cytokine storm, as signified by its increase in the process. Considering the role of IL-6 as a pro-inflammatory cytokine in the process of cytokine storm in COVID-19, perceiving IL-6 as a therapeutic target could prove to be promising. Tocilizumab is a monoclonal antibody that competitively inhibits the binding of IL-6 to its receptor (IL-6R). The use of IL-6R blocker is recommended for severe COVID-19 patients in the latest therapeutic guideline published by the World Health Organization (WHO), but the timing of the administration has not been specified. While previous studies about the use of tocilizumab in COVID-19 patients have shown various results, these studies do not emphasize on plasma IL-6 levels when deciding the time of tocilizumab administration. In this case series, we present three patients with moderate to severe COVID-19 infections that receive tocilizumab as an adjunct to the standard of care therapy. This case series introduces the novel idea that the timely use of tocilizumab as signified by plasma IL-6 levels in moderate to severe COVID-19 patients could potentially improve overall clinical condition and increase survival rate.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2021-10-04</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1854</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 53 No. 3 (2021): Acta Medica Indonesiana; 319</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1854/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2021 Eric Daniel Tenda</dc:rights>
</oai_dc:dc>